Drug Profile

Research programme: insulin-like growth factor therapeutics - Insmed

Alternative Names: rhIGBP-3 - Insmed

Latest Information Update: 13 Apr 2012

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Insmed
Class Recombinant proteins
Mechanism of Action Insulin like growth factor binding protein 3 modulators; Insulin-like growth factor I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
Available For Licensing Yes

13 Apr 2012 Research programme: insulin-like growth factor therapeutics - Insmed is available for licensing as of 13 Mar 2012. http://www.insmed.com/
21 Mar 2005 Preclinical trials in Prostate cancer in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com